Reactive Oxygen Species in Development of Ovarian Cancer: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
David C. Stieg
,
Yifang Wang
,
Ling-Zhi Liu
,
Bing-Hua Jiang

Ovarian cancer (OC) is a heterogeneous disease with several subtypes that differ in their gene expression, tumor origin, pathway alterations, and pathogenesis. Reactive oxygen species (ROS) are oxygen ions with unpaired electrons (singlet oxygen 1O2, superoxide O2·−) or oxygen-containing molecules, such as hydroxyl radicals (OH·−), hydrogen peroxide (H2O2), nitric oxide (NO), and nitrogen dioxide (NO2).

  • ovarian cancer
  • miRNA dysregulation
  • ROS
  • HIF-1
  • microRNAs
  • angiogenesis
  • therapeutic resistance

1. Ovarian Cancer

Known as the silent killer, ovarian cancer (OC) has the lowest survival rate and the worst prognosis among all gynecologic malignancies in the US; and is the eighth most common cancer in women worldwide [1][2]. In 2022, the American Cancer Society estimates about 21,000 new cases of OC will be diagnosed, and approximately 14,000 women will die from this type of cancer. The overall 5-year survival rate is only 48% due to OC’s ambiguous symptoms and inadequate screening capabilities at the early stages of the disease. Due to late detection, about 60% of new cases are diagnosed when the disease has already progressed to the advanced stage [2]. OC is a heterogeneous disease with several subtypes that differ in their gene expression, tumor origin, pathway alterations, and pathogenesis. The majority of OC originates from three main cell types: epithelial cells (90%), stromal cells (7%), and germ cells (3%) [1][3][4]. In general, epithelial OC can be further divided into five histotypes: high-grade serous (HGSOC; 70%), endometrioid (ENOC; 10%), clear cell (CCOC; 10%), mucinous (MOC; 5%), and low-grade serous (LGSOC; less than 5%) OC [4]. In addition, another classification system was introduced a decade ago that divided OC into type I and II tumors. Type I tumors are low-grade neoplasms, including mucinous carcinomas, endometrioid carcinomas, malignant Brenner tumors, and clear cell carcinomas. Type I tumors are typically characterized by mutations in BRAF, KRAS, and PTEN with DNA instability. Type II tumors are high-grade serous carcinoma, carcinosarcoma, and undifferentiated carcinoma, which are frequently observed with mutations in p53, BRCA1/2, HER-2/HER-3 overexpression, and p16 inactivation [5][6][7][8]. Depending on the specific subtype and histopathology, OC treatment involves a combination of surgery and chemotherapy. For patients with advanced-stage tumors, debulking surgery is recommended; however, large tumors or residual tumors may show negative side effects leading to blockage of the perfusion area and the possibility of developing drug resistance [1][9]. Platinum-based chemotherapy is the standard line of treatment for OC, either in conjunction with or following surgery [10][11][12]. The combination of paclitaxel/carboplatin has been recognized as the standard postoperative chemotherapy for many years [13]. In recent years, PARP inhibitors have been incorporated into clinical treatment as a recommended maintenance drug [14]. However, due to the aggressive growth rates and the propensity of advanced tumors to evade treatment, there are critical limitations to the current lines of therapy. A better understanding of the molecular biology of OC is allowing more research efforts to establish new effective treatment options for advanced-stage tumors.

2. Reactive Oxygen Species

Reactive oxygen species (ROS) have remained a highly relevant topic over the last few decades due to their expansive effects on normal cellular function. Oxidative stress is generated through the accumulation of ROS, either through exogenous exposure or endogenous production. ROS are oxygen ions with unpaired electrons (singlet oxygen 1O2, superoxide O2·−) or oxygen-containing molecules, such as hydroxyl radicals (OH·−), hydrogen peroxide (H2O2), nitric oxide (NO), and nitrogen dioxide (NO2) [15]. Superoxide radicals are converted into H2O2 by the enzyme superoxide dismutase (SOD). However, superoxide can also react with nitric oxide to produce peroxynitrite (ONOO−), a strong oxidizer with damaging cellular effects [16]. The accumulation of H2O2 has detrimental effects on nuclear and mitochondrial DNA, which may lead to genetic instability to drive cancer progression with increased expression of oncogenes and decreased expression of tumor suppressors [17][18]. Several enzymes work in conjunction to convert H2O2 into the water, including catalase, glutathione peroxidases 1 and 4, and peroxiredoxins 3 and 5 [19][20][21][22]. Furthermore, H2O2 can also participate in the Fenton reaction, in which free iron Fe(II) reacts with H2O2, generating highly reactive hydroxyl radicals (·OH)(shown below). The production of hydroxyl radicals (·OH) by the Haber–Weiss reaction (shown below) further perpetuates the damaging effects of the accumulation of ROS.
Fenton Reaction:
Fe(II) + H2O2 ⟷ Fe(III) + ·OH + OH−
Haber–Weiss Reaction:
O2·− + H2O2 ⟷ OH + OH− + O2
Original studies implicated the mitochondria as primary endogenous sources of superoxide through the process of cellular respiration, a process dependent on the availability of O2 [23][24][25]. Based on this view, the production of ROS was thought to be a harmful by-product of intracellular metabolism. Then a family of transmembrane enzymes known as NADPH oxidase (NOX) proteins was identified, whose primary function was the production of endogenous ROS. NOX2, the first NOX protein discovered, was the primary producer of endogenous ROS in leukocytes to generate an oxidative burst, an essential process for the neutralization of pathogens [26][27][28][29]. The characterization of a disease called chronic granulomatous disease (CGD) caused by a mutation in the phagocytic NOX gene provided insight into the emerging role of endogenous ROS production on cellular functionality [30][31]. Subsequent work demonstrated a pivotal role of NOX proteins in mammalian cell transformation through the production of superoxide radicals and H2O2 [32][33]. The researcher group demonstrated that the accumulation of ROS in OC cells was attributed to H2O2 increased levels induced by NOX4 [34], identifying an endogenous mechanism for the overproduction of ROS and alteration of intracellular signaling in OC tumor development.
Under normal cellular conditions, low levels of endogenous ROS activate several signaling pathways involved in cell proliferation. However, the accumulation of ROS causes extensive damage to DNA, RNA, proteins, and lipids, thus causing a significant hindrance to normal cellular functions and contributing to the development of multiple human pathologies [35][36][37][38]. The damage can induce cell death pathways or trigger the mutation of DNA, as commonly found in cancer [39][40]. In addition to the endogenous production of ROS and oxidative stress, external or environmental exposure to ROS can have detrimental effects on mammals [41]. For instance, many chemotherapeutic agents induce oxidative stress as a means of inducing cellular damage and cell death pathways [42]. However, as demonstrated by more recent findings, ROS play an important role in the progression and advancement of human diseases. The counterweight for endogenous ROS is the genetically programmed redox system. This includes groups of genes coding for antioxidant proteins such as superoxide dismutase (SOD), catalase, and the glutathione system, which neutralize the ROS produced in cells [43][44][45]. The failure to neutralize endogenous ROS leads to a build-up of harmful oxygen species and, consequently, oxidative stress. In normal cells, oxidative stress leads to deleterious cellular effects, such as protein, lipid, and DNA damage, organelle dysfunction, and cell cycle arrest [46]. Higher levels of oxidative stress cause the activation of cell death pathways such as apoptosis and necrosis [46], which may be mitigated in cancer cells by an increase in antioxidant production. The upregulation of nuclear factor erythroid 2-related factor 2 (NRF2), a master transcriptional regulator of antioxidant genes, contributes to the neutralization of endogenous ROS in OC cells [47][48][49], making NRF2 a viable target for chemotherapeutic treatment in certain cases of OC. In addition, the genetic mutation of cellular pathways that induce cell death mechanisms in response to increased oxidative stress allows cancer cells to evade the activation of cell death pathways [50], thus providing cancer cells the ability to continue continuous proliferation in the presence of adverse cellular conditions, such as oxidative stress.

3. ROS in the Development of Ovarian Cancer

There is an established link between an increase in ROS production and cancer development in humans [51]. As secondary cellular signaling molecules, ROS are involved in the activation of several signaling pathways involved in cell proliferation and growth. Consequently, these pathways are constitutively activated in cancer cells with increased ROS levels that contribute to tumorigenesis [51]. For example, endogenously derived ROS activate the ERK1/2 MAPK signaling pathway and the AKT signaling pathway in OC, both of which promote cell proliferation [52][53]. The increased ROS generation also contributes to a genetic mutation in cancer cells, further contributing to cell transformation [54][55]. As opposed to the traditional view of ROS generation in cancer as a harmful secondary by-product, the increasing knowledge of cancer cell metabolism and signal transduction is exposing ROS as a positive contributing factor in tumorigenesis and cancer development. The increased metabolic activity of cancer cells was originally thought to be responsible for the accumulation of ROS as a byproduct of increased glycolytic metabolism and mitochondrial respiration [56]. However, the discovery of the role of NOX proteins in endogenous ROS production revealed a more important role for ROS production in non-phagocytic cells, particularly in cancer [57][58][59]. The endogenous production of ROS by NOX1 was found to be responsible for increased viability and proliferation in colon cancer [60][61]. Similarly, the role of NOX2-mediated ROS production was discovered to be critical for cell viability and proliferation in breast, colorectal, myelomonocytic leukemia, gastric, and prostate cancers [62][63][64][65][66][67]. NOX4 overexpression contributed to an oncogenic proliferation in renal cell carcinoma, melanoma, glioblastoma, ovarian, prostate, and lung cancers [34][68][69][70][71][72]. In OC cell lines, there is a significant increase in ROS production, which contributes to tumorigenesis [34]. The increase in ROS is a result of NADPH oxidase activity and mitochondrial metabolism, as this increase is diminished by NADPH oxidase and mitochondrial complex I inhibitors [34]. Moreover, the increased levels of ROS result from the upregulation of the NADPH oxidase subunit NOX4, which serves as the main contributor to ROS production in OC cells to promote tumor growth and angiogenesis [34]. Furthermore, the activation of NOX4 is positively correlated with TGF-β1 and NF-κB activity, which is suppressed by their inhibitors [34]. This system demonstrates that endogenous NOX4-derived ROS are a driving force in OC development. Moreover, NOX4 is a potential target for the therapeutic resistance of OC which is dependent on ROS production for an increase in oncogenic signaling.

This entry is adapted from the peer-reviewed paper 10.3390/ijms23126702

References

  1. Stewart, C.; Ralyea, C.; Lockwood, S. Ovarian Cancer: An Integrated Review. Semin. Oncol. Nurs. 2019, 35, 151–156.
  2. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33.
  3. Chen, V.W.; Ruiz, B.; Killeen, J.L.; Coté, T.R.; Wu, X.C.; Correa, C.N.; Howe, H.L. Pathology and classification of ovarian tumors. Cancer 2003, 97, 2631–2642.
  4. Reid, B.M.; Permuth, J.B.; Sellers, T.A. Epidemiology of Ovarian Cancer: A Review. Cancer Biol. Med. 2017, 14, 9–32.
  5. Banerjee, S.; Kaye, S.B. New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential. Clin. Cancer Res. 2013, 19, 961–968.
  6. Jayson, G.C.; Kohn, E.C.; Kitchener, H.C.; Ledermann, J.A. Ovarian Cancer. Lancet 2014, 384, 1376–1388.
  7. Shih, I.M.; Kurman, R.J. Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis. Am. J. Pathol. 2004, 164, 1511–1518.
  8. Rocco, J.W.; Sidransky, D. P16(Mts-1/Cdkn2/Ink4a) in Cancer Progression. Exp. Cell Res. 2001, 264, 42–55.
  9. Berek, J.S.; Kehoe, S.T.; Kumar, L.; Friedlander, M. Cancer of the Ovary, Fallopian Tube, and Peritoneum. Int. J. Gynecol. Obstet. 2018, 143 (Suppl. 2), 59–78.
  10. Bookman, M.A.; McGuire, W.P., 3rd; Kilpatrick, D.; Keenan, E.; Hogan, W.M.; Johnson, S.W.; O’Dwyer, P.; Rowinsky, E.; Gallion, H.H.; Ozols, R.F. Carboplatin and Paclitaxel in Ovarian Carcinoma: A Phase I Study of the Gynecologic Oncology Group. J. Clin. Oncol. 1996, 14, 1895–1902.
  11. Bookman, M.A.; Brady, M.F.; McGuire, W.P.; Harper, P.G.; Alberts, D.S.; Friedlander, M.; Colombo, N.; Fowler, J.M.; Argenta, P.A.; De Geest, K.; et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. J. Clin. Oncol. 2009, 27, 1419–1425.
  12. Ozols, R.F.; Bundy, B.N.; Greer, B.E.; Fowler, J.M.; Clarke-Pearson, D.; Burger, R.A.; Mannel, R.S.; DeGeest, K.; Hartenbach, E.M.; Baergen, R.; et al. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2003, 21, 3194–3200.
  13. McGuire, W.P.; Hoskins, W.J.; Brady, M.F.; Kucera, P.R.; Partridge, E.E.; Look, K.Y.; Clarke-Pearson, D.L.; Davidson, M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 1996, 23 (Suppl. 2), 40–47.
  14. Armstrong, D.K.; Alvarez, R.D.; Bakkum-Gamez, J.N.; Barroilhet, L.; Behbakht, K.; Berchuck, A.; Chen, L.-M.; Cristea, M.; DeRosa, M.; Eisenhauer, E.L.; et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2021, 19, 191–226.
  15. D’Autréaux, B.; Toledano, M.B. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 2007, 8, 813–824.
  16. Beckman, J.S.; Beckman, T.W.; Chen, J.; Marshall, P.A.; Freeman, B.A. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 1990, 87, 1620–1624.
  17. Negrini, S.; Gorgoulis, V.G.; Halazonetis, T.D. Genomic Instability—An Evolving Hallmark of Cancer. Nat. Rev. Mol. Cell Biol. 2010, 11, 220–228.
  18. Van Houten, B.; Woshner, V.; Santos, J.H. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair 2006, 5, 145–152.
  19. Hurd, T.R.; Costa, N.J.; Dahm, C.; Beer, S.M.; Brown, S.E.; Filipovska, A.; Murphy, M. Glutathionylation of Mitochondrial Proteins. Antioxidants Redox Signal. 2005, 7, 999–1010.
  20. Rhee, S.G.; Kang, S.W.; Chang, T.-S.; Jeong, W.; Kim, K. Peroxiredoxin, a Novel Family of Peroxidases. IUBMB Life 2001, 52, 35–41.
  21. Rhee, S.G.; Yang, K.S.; Kang, S.W.; Woo, H.A.; Chang, T.S. Controlled Elimination of Intracellular H2O2: Regulation of Peroxiredoxin, Catalase, and Glutathione Peroxidase Via Post-Translational Modification. Antioxid. Redox Signal. 2005, 7, 619–626.
  22. Imai, H.; Nakagawa, Y. Biological Significance of Phospholipid Hydroperoxide Glutathione Peroxidase (Phgpx, Gpx4) in Mammalian Cells. Free. Radic. Biol. Med. 2003, 34, 145–169.
  23. Loschen, G.; Flohe, L.; Chance, B. Respiratory Chain Linked H2O2 Production in Pigeon Heart Mitochondria. FEBS Lett. 1971, 18, 261–264.
  24. Skulachev, V.P. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. Q. Rev. Biophys. 1996, 29, 169–202.
  25. Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417, 1–13.
  26. Rossi, F.; Zatti, M. Biochemical aspects of phagocytosis in poly-morphonuclear leucocytes. NADH and NADPH oxidation by the granules of resting and phagocytizing cells. Experientia 1964, 20, 21–23.
  27. Quie, P.G.; White, J.G.; Holmes, B.; Good, R.A. In Vitro Bactericidal Capacity of Human Polymorphonuclear Leukocytes: Diminished Activity in Chronic Granulomatous Disease of Childhood *. J. Clin. Investig. 1967, 46, 668–679.
  28. Baehner, R.L.; Nathan, D.G. Leukocyte Oxidase: Defective Activity in Chronic Granulomatous Disease. Science 1967, 155, 835–836.
  29. Holmes, B.; Page, A.R.; Good, R.A. Studies of the Metabolic Activity of Leukocytes from Patients with a Genetic Abnormality of Phagocytic Function*. J. Clin. Investig. 1967, 46, 1422–1432.
  30. Berendes, H.; Bridges, R.A.; Good, R.A. A fatal granulomatosus of childhood: The clinical study of a new syndrome. Minn. Med. 1957, 40, 309–312.
  31. Royer-Pokora, B.; Kunkel, L.M.; Monaco, A.; Goff, S.C.; Newburger, P.; Baehner, R.L.; Cole, F.S.; Curnutte, J.T.; Orkin, S.H. Cloning the gene for an inherited human disorder—Chronic granulomatous disease—On the basis of its chromosomal location. Nature 1986, 322, 32–38.
  32. Suh, Y.-A.; Arnold, R.S.; Lassegue, B.; Shi, J.; Xu, X.X.; Sorescu, D.; Chung, A.B.; Griendling, K.K.; Lambeth, J.D. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999, 401, 79–82.
  33. Lambeth, J.; Cheng, G.; Arnold, R.S.; Edens, W.A. Novel homologs of gp91phox. Trends Biochem. Sci. 2000, 25, 459–461.
  34. Xia, C.; Meng, Q.; Liu, L.-Z.; Rojanasakul, Y.; Wang, X.-R.; Jiang, B.-H. Reactive Oxygen Species Regulate Angiogenesis and Tumor Growth through Vascular Endothelial Growth Factor. Cancer Res. 2007, 67, 10823–10830.
  35. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160, 1–40.
  36. Paravicini, T.M.; Touyz, R.M. Nadph Oxidases, Reactive Oxygen Species, and Hypertension: Clinical Implications and Therapeutic Possibilities. Diabetes Care 2008, 31 (Suppl. 2), S170–S180.
  37. Martínez, M.C.; Andriantsitohaina, R. Reactive Nitrogen Species: Molecular Mechanisms and Potential Significance in Health and Disease. Antioxidants Redox Signal. 2009, 11, 669–702.
  38. Cross, C.E.; Halliwell, B.; Borish, E.T.; Pryor, W.A.; Ames, B.N.; Saul, R.L.; Mccord, J.M.; Harman, D. Oxygen Radicals and Human Disease. Ann. Intern. Med. 1987, 107, 526–545.
  39. Johnson, T.M.; Yu, Z.X.; Ferrans, V.J.; Lowenstein, R.A.; Finkel, T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 1996, 93, 11848–11852.
  40. Dizdaroglu, M. Oxidatively Induced DNA Damage and Its Repair in Cancer. Mutat. Res. Rev. Mutat. Res. 2015, 763, 212–245.
  41. Peluso, M.; Russo, V.; Mello, T.; Galli, A. Oxidative Stress and DNA Damage in Chronic Disease and Environmental Studies. Int. J. Mol. Sci. 2020, 21, 6936.
  42. Yang, H.; Villani, R.M.; Wang, H.; Simpson, M.J.; Roberts, M.S.; Tang, M.; Liang, X. The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res. 2018, 37, 266.
  43. Copin, J.-C.; Gasche, Y.; Chan, P.H. Overexpression of copper/zinc superoxide dismutase does not prevent neonatal lethality in mutant mice that lack manganese superoxide dismutase. Free Radic. Biol. Med. 2000, 28, 1571–1576.
  44. Maiorino, F.M.; Brigelius-Flohé, R.; Aumann, K.; Roveri, A.; Schomburg, D.; Flohé, L. Diversity of Glutathione Peroxidases. Methods Enzymol. 1995, 252, 38–53.
  45. Arnér, E.S.J.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. BioChem. 2000, 267, 6102–6109.
  46. Ray, P.D.; Huang, B.-W.; Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell. Signal. 2012, 24, 981–990.
  47. Khalil, H.S.; Goltsov, A.; Langdon, S.P.; Harrison, D.J.; Bown, J.; Deeni, Y. Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells. J. Biotechnol. 2015, 202, 12–30.
  48. Liew, P.-L.; Hsu, C.-S.; Liu, W.-M.; Lee, Y.-C.; Lee, Y.-C.; Chen, C.-L. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma. Int. J. Clin. Exp. Pathol. 2015, 8, 5642–5649.
  49. Czogalla, B.; Kahaly, M.; Mayr, D.; Schmoeckel, E.; Niesler, B.; Kolben, T.; Burges, A.; Mahner, S.; Jeschke, U.; Trillsch, F. Interaction of Eralpha and Nrf2 Impacts Survival in Ovarian Cancer Patients. Int. J. Mol. Sci. 2018, 20, 112.
  50. Thompson, C.B. Apoptosis in the Pathogenesis and Treatment of Disease. Science 1995, 267, 1456–1462.
  51. Moloney, J.N.; Cotter, T.G. ROS signalling in the biology of cancer. Semin. Cell Dev. Biol. 2018, 80, 50–64.
  52. Chan, D.W.; Liu, V.W.; Tsao, G.S.; Yao, K.-M.; Furukawa, T.; Chan, K.K.; Ngan, H.Y. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 2008, 29, 1742–1750.
  53. Liu, L.-Z.; Hu, X.-W.; Xia, C.; He, J.; Zhou, Q.; Shi, X.; Fang, J.; Jiang, B.-H. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic. Biol. Med. 2006, 41, 1521–1533.
  54. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44–84.
  55. Tudek, B.; Winczura, A.; Janik, J.; Siomek, A.; Foksinski, M.; Oliński, R. Involvement of oxidatively damaged DNA and repair in cancer development and aging. Am. J. Transl. Res. 2010, 2, 254–284.
  56. Fridovich, I. The biology of oxygen radicals. Science 1978, 201, 875–880.
  57. Meier, B.; Cross, A.R.; Hancock, J.T.; Kaup, F.J.; Jones, O.T.G. Identification of a superoxide-generating NADPH oxidase system in human fibroblasts. Biochem. J. 1991, 275, 241–245.
  58. Szatrowski, T.P.; Nathan, C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51, 794–798.
  59. Griendling, K.K.; Minieri, C.A.; Ollerenshaw, J.D.; Alexander, R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 74, 1141–1148.
  60. De Carvalho, D.D.; Sadok, A.; Bourgarel-Rey, V.; Gattacceca, F.; Penel, C.; Lehmann, M.; Kovacic, H. Nox1 downstream of 12-lipoxygenase controls cell proliferation but not cell spreading of colon cancer cells. Int. J. Cancer 2008, 122, 1757–1764.
  61. Kajla, S.; Mondol, A.S.; Nagasawa, A.; Zhang, Y.; Kato, M.; Matsuno, K.; Matsuno, K.; Yabe-Nishimura, C.; Kamata, T. A Crucial Role for Nox 1 in Redox-Dependent Regulation of Wnt-Beta-Catenin Signaling. FASEB J. 2012, 26, 2049–2059.
  62. Mukawera, E.; Chartier, S.; Williams, V.; Pagano, P.J.; Lapointe, R.; Grandvaux, N. Redox-Modulating Agents Target Nox2-Dependent Ikkepsilon Oncogenic Kinase Expression and Proliferation in Human Breast Cancer Cell Lines. Redox Biol. 2015, 6, 9–18.
  63. Banskota, S.; Regmi, S.C.; Kim, J.-A. NOX1 to NOX2 switch deactivates AMPK and induces invasive phenotype in colon cancer cells through overexpression of MMP-7. Mol. Cancer 2015, 14, 123.
  64. Wiktorin, H.G.; Nilsson, T.; Aydin, E.; Hellstrand, K.; Palmqvist, L.; Martner, A. Role of NOX2 for leukaemic expansion in a murine model of BCR-ABL1 + leukaemia. Br. J. Haematol. 2018, 182, 290–294.
  65. Hole, P.S.; Zabkiewicz, J.; Munje, C.; Newton, Z.; Pearn, L.; White, P.; Marquez, N.; Hills, R.; Burnett, A.K.; Tonks, A.; et al. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 2013, 122, 3322–3330.
  66. Harrison, I.P.; Vinh, A.; Johnson, I.; Luong, R.; Drummond, G.R.; Sobey, C.G.; Tiganis, T.; Williams, E.; O’Leary, J.; Brooks, D.; et al. NOX2 oxidase expressed in endosomes promotes cell proliferation and prostate tumour development. Oncotarget 2018, 9, 35378–35393.
  67. Kim, S.-M.; Hur, D.Y.; Hong, S.-W.; Kim, J.H. EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells. Biochem. Biophys. Res. Commun. 2017, 494, 550–555.
  68. Block, K.; Gorin, Y.; Hoover, P.; Williams, P.; Chelmicki, T.; Clark, R.A.; Yoneda, T.; Abboud, H.E. NAD(P)H Oxidases Regulate HIF-2α Protein Expression. J. Biol. Chem. 2007, 282, 8019–8026.
  69. Brar, S.S.; Kennedy, T.P.; Sturrock, A.B.; Huecksteadt, T.P.; Quinn, M.T.; Whorton, A.R.; Hoidal, J.R. An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am. J. Physiol. Physiol. 2002, 282, C1212–C1224.
  70. Diaz, B.; Shani, G.; Pass, I.; Anderson, D.; Quintavalle, M.; Courtneidge, S.A. Tks5-Dependent, Nox-Mediated Generation of Reactive Oxygen Species Is Necessary for Invadopodia Formation. Sci. Signal. 2009, 2, ra53.
  71. Ogrunc, M.; Di Micco, R.; Liontos, M.; Bombardelli, L.; Mione, M.; Fumagalli, M.; Gorgoulis, V.G.; Daddadifagagna, F. Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ. 2014, 21, 998–1012.
  72. Zhang, C.; Lan, T.; Hou, J.; Li, J.; Fang, R.; Yang, Z.; Zhang, M.; Liu, J.; Liu, B. NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling. Oncotarget 2014, 5, 4392–4405.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback